Effect of New Chinese Medicine Compound Jiangya Kangxian Decoction Constructed Based on Network Pharmacology

Chen Kai; LIU Xin; GUAN Yi-qing; ZHUANG Yu-xin; DANG Wen-zhen; LYU Lin; ZHANG Guo-hua

doi:10.13422/j.cnki.syfjx.20182041

您当前的位置：

首页 >

文章列表页 >

Effect of New Chinese Medicine Compound Jiangya Kangxian Decoction Constructed Based on Network Pharmacology

更新时间：2024-01-04

- Effect of New Chinese Medicine Compound Jiangya Kangxian Decoction Constructed Based on Network Pharmacology
- Chinese Journal of Experimental Traditional Medical Formulae Vol. 24, Issue 20, Pages: 115-122(2018)
- 作者机构：
- 作者简介：
- 基金信息：
- DOI：10.13422/j.cnki.syfjx.20182041
  CLC： R285
- Published：2018
- 稿件说明：
移动端阅览
Chen Kai, LIU Xin, GUAN Yi-qing, et al. Effect of New Chinese Medicine Compound Jiangya Kangxian Decoction Constructed Based on Network Pharmacology[J]. Chinese journal of experimental traditional medical formulae, 2018, 24(20): 115-122.
DOI：

Chen Kai, LIU Xin, GUAN Yi-qing, et al. Effect of New Chinese Medicine Compound Jiangya Kangxian Decoction Constructed Based on Network Pharmacology[J]. Chinese journal of experimental traditional medical formulae, 2018, 24(20): 115-122. DOI： 10.13422/j.cnki.syfjx.20182041.

摘要

目的：结合网络药理学和传统中医理论构建治疗高血压心肌纤维化的新型中药复方——降压抗纤方，并探讨其对自发性高血压大鼠（SHR）心肌纤维化的治疗效果。方法：获取中药网络药理学数据库中药系统药理学数据库和分析平台（TCMSP）中的中药、成分和靶标等信息，运用网络分析软件Cytoscape从中筛选出能作用于高血压心肌纤维化疾病靶标的中药，再根据中医辨证理论和组方原则进一步筛选并构建复方。通过SHR动物模型实验观察降压抗纤方抗心机纤维化的作用，以5只正常血压大鼠（normal blood pressure rat，WKY）为空白组，30只12周龄的SHR大鼠随机分为5组，分别为高血压模型组（SHR），降压抗纤方低剂量组（KXL，2 g·kg-1），降压抗纤方中剂量组（KXM，4 g·kg-1），降压抗纤方高剂量组（KXH，8 g·kg-1）和卡托普利阳性药组（CAP，13.5 mg·kg-1），每组5只。连续灌胃12周后停药，取材前禁食12 h。运用大鼠无创尾压仪和彩色多普勒超声诊断仪检测血压及心脏功能，运用组织学染色和相应检测试剂盒观察心脏组织形态学改变及血清生化指标。结果：确认降压抗纤方组成成分为丹参、三七、黄芪、鸡血藤和化橘红。动物实验结果表明，与正常组比较，模型组的血压明显升高（P<0.01），心脏功能指标下降（P<0.01），同时血清中心肌酶谱的水平升高（P<0.05，P<0.01），炎症因子水平升高（P<0.05，P<0.01）；与模型组比较，各给药组能有效逆转上述指标（P<0.05，P<0.01）。结论：运用网络药理学和传统中医理论所构建的新型复方降压抗纤方具有抗高血压心肌纤维化的作用，并对肝肾无毒副作用。

Abstract

Objective: To develop new Chinese medicine compound Jiangya Kangxian decoction for the treatment of hypertensive myocardial fibrosis using network pharmacology and traditional Chinese medicine (TCM) theory

in order to explore its therapeutic effect on hypertensive myocardial fibrosis in spontaneously hypertensive rats (SHR).Method: Data of Chinese herbs

ingredients

targets and diseases was obtained from traditional Chinese medine systems pharmacology (TCMSP) databases. Chinese herbs that can act on targets of hypertension and myocardial fibrosis were selected using Cytoscape

and then further screened out according to TCM theory of syndrome differentiation

in order to into a new Chinese medicine compound on the basis of the principles of formula composition. Five rats with normal blood pressure (WKY) were taken as blank group; 30 12-week-old SHR rats were taken as the study object and randomly divided into five groups:spontaneous hypertensive rat group (SHR)

low-dose Jiangya Kangxian decoction group (KXL

2 g·kg-1)

moderate-dose Jiangya Kangxian decoction group (KXM

4 g·kg-1)

high-dose Jiangya Kangxian decoction group (KXH

8 g·kg-1) and captopril positive control group (CAP

13.5 mg·kg-1). The rats were orally administered with drugs for consecutively 20 weeks and then fasted for 12 h before being put to death.The noninvasive tail voltmeter and Color Doppler were used to detect blood pressure and cardiac function. Tissue staining and biochemical kit were used to observed heart histomorphology and serum biochemical indexes.Result: It was confirmed that Jiangya Kangxian decoction consists of Salviae Miltiorrhizae Radix et Rhizoma

Notoginseng Radix et Rhizoma

Astragali Radix

Spatholobi Caulis and Citri Grandis Exocarpium. The results of animal experiments showed that

compared with the normal group

the blood pressure of the model group increased significantly (P<0.01)

the cardiac function index decreased (P<0.01)

the levels of serum myocardial enzymes increased (P<0.05

P<0.01)

and the level of inflammatory factors was increased (P<0.05

P<0.01). Compared with the model group

each drug group could effectively reverse the above indicators (P<0.05

P<0.01).Conclusion: Jiangya Kangxian decoction constructed by network pharmacology and TCM theory has a therapeutic effect on hypertensive myocardial fibrosis in SHR

with no side effects on liver and kidney.

关键词

Keywords

references

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Effect of Guizhitang with Different Proportions of Cinnamomi Ramulus and Paeoniae Alba Radix in Regulating TGF-β₁/Smads Signaling Pathway and Chronic Inflammation and Alleviating Myocardial Fibrosis in Salt-sensitive Hypertensive Rats

Histopathological Observation of Renal Arteriole for Effect of Compound Calculus Bovis Depressurization Formula on Spontaneous Hypertensive Rats

Invasion and Metastasis Inhibition of Lung Cancer by Traditional Chinese Medicine： A Review

Clinical Efficacy and Mechanism of Compound Langdu Tincture in Treating Multiple Palmoplantar Warts of Dampness-toxin Accumulation Type

Excavation of New Prescription for Chronic Atrophic Gastritis and Its Verification of Syndrome Type of Deficiency of Stomach Yin

Related Author

Ji-ye CHEN

Guo-feng ZHOU

Yong-cheng WANG

Du-fang MA

Chen-yu CHI

Xiao-wei HAN

Yong-jian ZHANG

Xiao LI

Related Institution

Shandong University of Traditional Chinese Medicine

Affiliated Hospital of Shandong University of Traditional Chinese Medicine

The Second Clinical Medical College， Henan University of Chinese Medicine

The Affiliated Cancer Hospital of Zhengzhou University/Henan Cancer Hospital

The First Affiliated Hospital of Zhejiang Chinese Medical University （Zhejiang Provincial Hospital of Chinese Medicine）

AI问答

Postal code：100700
Tel：010-84076882 Email：syfjx_2010@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备11006657号-10 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰